Novartis Refuses To Yank Gleevec Lawsuit

Law360, New York (March 6, 2007, 12:00 AM EST) -- Standing strong in the face of international pressure, Novartis AG has refused to withdraw its controversial Gleevec lawsuit in India but has slightly modified its stance against a key section of the country’s patent laws.

In arguments in the Madras High Court on Monday, the drug maker said the company was not opposed to Section 3(d) of India’s Patents Amendment Act in its entirety, but rather to its interpretation, Daily News & Analysis reported.

The pharmaceutical giant had previously lobbied the court to declare Section 3(d)—which...
To view the full article, register now.